Society Pick of The Week

INmune Bio Inc. (NASDAQ: INMB)

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient’s innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach to promote the body’s innate immune response to treat unsolved problems in medicine.

Considerations:

• INmune Bio’s IPO closed Feb. 1, 2019, with NASDAQ Capital Markets listing on Feb. 4, 2019
• Public clinical-stage immunology company with programs in oncology and neurodegenerative disease
• INmune Bio targets large markets with unsolved problems such as resistance to checkpoint inhibitor therapy, a fast-growing oncology market segment; MRD, the cause of cancer relapse; and neuroinflammation as a cause of Alzheimer’s disease
• Receiver of “Part the Cloud” $1 million grant awarded by Alzheimer’s Association
• Experienced leadership with extensive experience in the targeted fields of clinical research and drug development
• Intellectual property with multiple filings in process for INB03/XPro1595 and INKmune
• Insider led round at $9/share for approximately $4.6 million in May.
• Genprex had a cash position of $10.3 million as of September 30, 2018.